Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Alzheimer's pill shows promise in Mid-Stage trial

NCT ID NCT06721156

Symptom relief Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests whether adding MK-1167 to standard Alzheimer's treatment can improve memory and thinking in people with mild to moderate Alzheimer's dementia. About 350 participants will receive either MK-1167 or a placebo for 24 weeks. Researchers will measure changes in cognitive function and track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MK-1167
What this could lead to
If it works, this could point toward a new add-on treatment to help slow mental decline in people with mild to moderate Alzheimer's dementia.
What could go wrong
This is an early Phase 2 trial, so results may not confirm benefit. The drug is tested only alongside existing therapy, and side effects or lack of improvement are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

369 people

The number who actually took part.

Started

Dec 2024

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has mild to moderate Alzheimer's Disease (AD) dementia (ie, Stage 4 or Stage 5 AD) based on the Alzheimer's Association Revised Criteria for Diagnosis and Staging of Alzheimer's Disease * Has a Mini-Mental State Examination (MMSE) score of 12 to 24 (inclusive) * Is using acetylcholinesterase inhibitors (AChEI) therapy for management of AD dementia * Has a designated study partner who can fulfill the requirements of this study. The study partner will need to spend sufficient time with the participant to be familiar with their overall function and behavior and be able to provide adequate information about the participant needed for the study including, knowledge of functional and basic activities of daily life, work/educational history, cognitive performance, emotional/psychological state, and general health status Exclusion Criteria: * Has a known history of stroke or cerebrovascular disease * Has diagnosis of a clinically relevant central nervous system (CNS) disease other than AD dementia or other condition that negatively impacts cognition or cognitive status chronically * Has structural brain disease * Has a history of seizures or epilepsy * Has any other major CNS trauma, or infections that affect brain function (eg, Human immunodeficiency virus (HIV), syphilis, and/or neurological sequelae of Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (COVID-19), including impact on cognition) * Has major medical illness or unstable medical condition * Has a history of malignancy * Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision (with protocol-specified exceptions) * Has liver disease, including but not limited to chronic viral hepatitis, nonviral hepatitis, cirrhosis, malignancies, autoimmune liver diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Dementia

Contacts and locations

Locations

  • Anderson Clinical Research ( Site 0164)

    Redlands, California, 92374, United States

  • Aqualane Clinical Research ( Site 0116)

    Naples, Florida, 34105, United States

  • Asan Medical Center ( Site 1603)

    Seoul, 05505, South Korea

  • Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 1510)

    Kawasaki, Kanagawa, 210-0852, Japan

  • Banner Alzheimer's Institute ( Site 0110)

    Phoenix, Arizona, 85006, United States

  • Brain Matters Research ( Site 0151)

    Stuart, Florida, 34997, United States

  • Brain Matters Research-Neurology ( Site 0150)

    Delray Beach, Florida, 33445, United States

  • Brain Research Center Den Bosch B.V. ( Site 1002)

    's-Hertogenbosch, North Brabant, 5223 LA, Netherlands

  • Brain Research Center Zwolle ( Site 1003)

    Zwolle, Overijssel, 8025 AZ, Netherlands

  • Brain Research Center. ( Site 1001)

    Amsterdam, North Holland, 1081 GN, Netherlands

  • Brain Sciences Scotland Life Sciences-Aberdeen ( Site 1402)

    Aberdeen, Aberdeen City, AB25 2XE, United Kingdom

  • California Neuroscience Research ( Site 0118)

    Sherman Oaks, California, 91403, United States

  • Campus for Ageing and Vitality ( Site 1408)

    Newcastle upon Tyne, NE4 5PL, United Kingdom

  • CenExel iResearch, LLC ( Site 0134)

    Savannah, Georgia, 31405, United States

  • Centro S Giovanni Di Dio Fatebenefratelli ( Site 0904)

    Brescia, 25125, Italy

  • Centro de Atención Especializada Oroitu ( Site 1211)

    Algorta, Bizkaia, 48993, Spain

  • Columbus Memory Center ( Site 0197)

    Columbus, Georgia, 31909, United States

  • Enomoto Internal Medicine Clinic(Chofu) ( Site 1503)

    Chōfu, Tokyo, 182-0036, Japan

  • Flourish Research - Charlotte ( Site 0106)

    Matthews, North Carolina, 28105, United States

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico-UOSD Malattie Neurodegenerative ( Site 0903)

    Milan, Lombardy, 20122, Italy

  • Fondazione IRCCS San Gerardo dei Tintori ( Site 0902)

    Monza, Monza E Brianza, 20900, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0905)

    Roma, 00168, Italy

  • Fundació ACE ( Site 1206)

    Barcelona, 08034, Spain

  • Grayline Research Center ( Site 0105)

    Wichita Falls, Texas, 76309, United States

  • Hanyang University Seoul Hospital ( Site 1605)

    Seoul, 04763, South Korea

  • Hatsuta Neurology Clinic ( Site 1507)

    Hirakata, Osaka, 573-1121, Japan

  • Headlands Research Orlando ( Site 0169)

    Orlando, Florida, 32806, United States

  • Hospital Italiano de Buenos Aires ( Site 0209)

    Buenos Aires, Buenos Aires F.D., C1199ABD, Argentina

  • Hospital Universitari Vall D Hebron ( Site 1203)

    Barcelona, 08035, Spain

  • Hospital Universitari i Politecnic La Fe ( Site 1202)

    Valencia, Valencia, 46026, Spain

  • Hospital Universitario 12 de Octubre ( Site 1208)

    Madrid, Madrid, Comunidad de, 28041, Spain

  • Hospital Universitario Virgen de la Macarena ( Site 1210)

    Seville, 41009, Spain

  • Hospital de la Santa Creu i Sant Pau ( Site 1204)

    Barcelona, Catalonia, 8025, Spain

  • Indago Research & Health Center, Inc ( Site 0128)

    Hialeah, Florida, 33012, United States

  • Inha University Hospital ( Site 1601)

    Incheon, 22332, South Korea

  • Instituto Geriatrico Nuestra Señora de Las Nieves ( Site 0208)

    Buenos Aires, Buenos Aires F.D., C1427CCP, Argentina

  • Instituto Kremer ( Site 0202)

    Córdoba, X5004AOA, Argentina

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0207)

    Mar del Plata, Buenos Aires, B7600FZN, Argentina

  • Irvine Clinical Research ( Site 0104)

    Irvine, California, 92614, United States

  • Itsuki Hospital ( Site 1502)

    Tokushima, 770-0852, Japan

  • Iwaki Clinic ( Site 1518)

    Anan, Tokushima, 774-0014, Japan

  • JEM Research Institute / Headlands Research Network ( Site 0108)

    Atlantis, Florida, 33462, United States

  • K2 Medical Research ( Site 0103)

    Maitland, Florida, 32750, United States

  • K2 Medical Research ( Site 0165)

    Tampa, Florida, 33634, United States

  • K2 Medical Research THE VILLAGES ( Site 0166)

    Lady Lake, Florida, 32159, United States

  • Kawasaki Saiwai Clinic ( Site 1501)

    Kawasaki, Kanagawa, 212-0016, Japan

  • Kerwin Medical Center ( Site 0159)

    Dallas, Texas, 75231, United States

  • Mid Hudson Medical Research ( Site 0191)

    New Windsor, New York, 12553, United States

  • Moorgreen Hospital ( Site 1409)

    Southampton, Hampshire, SO30 3JB, United Kingdom

  • Nagomi Clinic ( Site 1506)

    Toyonaka, Osaka, 560-0004, Japan

  • Neuropsychiatric Research Center of Southwest Florida ( Site 0152)

    Fort Myers, Florida, 33912, United States

  • Northwest Clinical Research Center ( Site 0102)

    Bellevue, Washington, 98007, United States

  • Nozomi Memory Clinic ( Site 1504)

    Mitaka, Tokyo, 181-0013, Japan

  • Okanagan Clinical Trials ( Site 0001)

    Kelowna, British Columbia, V1Y 1Z9, Canada

  • Organizacion Medica de Investigacion - OMI S.A. ( Site 0204)

    Buenos Aires, C1015ABO, Argentina

  • Ospedale San Raffaele. ( Site 0901)

    Milan, 20132, Italy

  • Ottawa Memory Clinic ( Site 0004)

    Ottawa, Ontario, K1Z 1G3, Canada

  • Pharmasite Research, Inc. ( Site 0167)

    Baltimore, Maryland, 21208, United States

  • Premier Clinical Research Institute ( Site 0114)

    Miami, Florida, 33122, United States

  • Quest Research Institute ( Site 0173)

    Farmington Hills, Michigan, 48334, United States

  • Re:Cognition Health - Birmingham ( Site 1406)

    Birmingham, B16 8LT, United Kingdom

  • Remind UK ( Site 1404)

    Bath, Somerset, BA1 3NG, United Kingdom

  • Scottish Brain Sciences ( Site 1401)

    Edinburgh, Edinburgh, City of, EH12 5PJ, United Kingdom

  • Seoul National University Hospital ( Site 1604)

    Seoul, 03080, South Korea

  • Summit Research Network ( Site 0111)

    Portland, Oregon, 97210, United States

  • Takesato Hospital ( Site 1522)

    Kasukabe, Saitama, 344-0036, Japan

  • Tandem Clinical Research ( Site 0101)

    Marrero, Louisiana, 70072, United States

  • Tokyo Metropolitan Institute for Geriatrics and Gerontology ( Site 1515)

    tabashi City, Tokyo, 173-0015, Japan

  • Toronto Memory Program ( Site 0006)

    Toronto, Ontario, M3B 2S7, Canada

  • Velocity Clinical Research - Raleigh ( Site 0123)

    Raleigh, North Carolina, 27607, United States

  • Velocity Clinical Research, Syracuse ( Site 0125)

    East Syracuse, New York, 13057, United States

  • Windsor Research Unit ( Site 1403)

    Cambridge, CB21 5EF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.